title: A randomized study of combining maze surgery for atrial fibrillation with mitral valve surgery.
abstract: OBJECTIVE
  Mitral valve surgery seldom suppresses atrial fibrillation (AF), present prior to surgery. Maze III surgery eliminates AF in >80% of cases, the reason why combining this procedure with mitral valve surgery in patients with AF seems worthwhile. We prospectively studied the outcome of combining the Maze III procedure with mitral valve surgery.
  
  
  METHODS
  Thirty-five patients with AF and a mean age of 64 years undergoing mitral valve surgery were prospectively randomized according to a 2.5:1 ratio to surgery with (n=25), or without (n=10) maze III and followed for at least 1 year.
  
  
  RESULTS
  At discharge and after 12 months freedom from AF was 56% and 92%, respectively, in the maze group, and 0% and 20%, respectively, in patients without maze (group differences at discharge p=0.002, after 12 months p=0.0007). Sinus node incompetence was seen in 1 of 25 maze patients requiring pacing. No in-hospital or late death occurred; stroke was observed in 1 patient (without maze). Quality of life markedly improved after surgery, but did not differ between patients with or without maze surgery.
  
  
  CONCLUSIONS
  This first prospective randomized study shows that combining maze III with mitral valve surgery resulted in a significantly better elimination of preoperative AF than mitral valve surgery alone. As the quality of life did not differ between patients with, or without maze surgery, additional maze surgery is primarily recommended in patients in whom anticoagulation therapy can be avoided after surgery, specifically in patients with scheduled mitral valve plasty.
authors.affiliation: Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.
authors.forename: E R
authors.initials: ER
authors.lastname: Jessurun
authors.forename: N M
authors.initials: NM
authors.lastname: van Hemel
authors.forename: J J
authors.initials: JJ
authors.lastname: Defauw
authors.forename: A
authors.initials: A
authors.lastname: Brutel De La Rivière
authors.forename: M A M
authors.initials: MA
authors.lastname: Stofmeel
authors.forename: J C
authors.initials: JC
authors.lastname: Kelder
authors.forename: J H
authors.initials: JH
authors.lastname: Kingma
authors.forename: J M P G
authors.initials: JM
authors.lastname: Ernst
mesh_terms: D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000601:surgery*; D006348:Cardiac Surgical Procedures / Q000009:adverse effects / Q000379:methods*; D015150:Echocardiography, Doppler; D004554:Electric Countershock; D015716:Electrocardiography, Ambulatory; D023381:Endpoint Determination; D005080:Exercise Test / Q000379:methods; D005260:Female; D006349:Heart Valve Diseases / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000473:pathology / Q000601:surgery*; D011183:Postoperative Complications; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D014859:Warfarin